GSTT1 null genotype increases risk of premenopausal breast cancer.
The NAT2, GSTM1 and GSTT1 genes are known candidate cancer susceptibility markers and have been investigated in breast cancer susceptibility with conflicting results. We conducted a case-control study to investigate the role of NAT2, GSTM1 and GSTT1 in premenopausal breast cancer. Women with the GSTT1 null genotype were found to have a significant 3.15-fold increased risk of breast cancer (95% CI = 1.7-5.8), while GSTM1 and NAT2 genotypes were not associated with breast cancer risk. Our results suggest that the GSTT1 null genotype may play a role in early onset breast cancer.
Matheson
Melanie C
MC
Department of Epidemiology and Preventive Medicine, Central and Eastern Clinical School, Alfred Hospital, Melbourne, Vic. 3151, Australia. melanie.matheson@med.monash.edu.au
Stevenson
Trevor
T
Akbarzadeh
Shiva
S
Propert
David N
DN
D000328:Adult; D001191:Arylamine N-Acetyltransferase / Q000235:genetics / Q000502:physiology; D001943:Breast Neoplasms / Q000201:enzymology / Q000235:genetics*; D016022:Case-Control Studies; D005260:Female; D005838:Genotype; D005982:Glutathione Transferase / Q000235:genetics* / Q000502:physiology; D006801:Humans; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D017697:Premenopause / Q000235:genetics* / Q000378:metabolism*; D012306:Risk
D001191:Arylamine N-Acetyltransferase; D005982:Glutathione Transferase; C478900:NAT2 protein, human; C413545:glutathione S-transferase T1